Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $8.08.

CLDX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $3.50 target price (down from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, May 11th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th.

A number of hedge funds have recently modified their holdings of CLDX. California State Teachers Retirement System raised its stake in shares of Celldex Therapeutics by 13.9% in the second quarter. California State Teachers Retirement System now owns 214,400 shares of the biopharmaceutical company’s stock worth $530,000 after buying an additional 26,200 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Celldex Therapeutics by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 99,535 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 21,355 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in shares of Celldex Therapeutics during the second quarter worth approximately $158,000. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Celldex Therapeutics by 5.6% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 105,817 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 5,632 shares in the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of Celldex Therapeutics by 17.4% in the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares in the last quarter. 63.88% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/19/celldex-therapeutics-inc-cldx-receives-average-recommendation-of-hold-from-analysts.html.

Celldex Therapeutics (NASDAQ:CLDX) traded down 1.27% during midday trading on Friday, reaching $2.33. The company had a trading volume of 726,077 shares. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $5.02. The company’s market capitalization is $299.03 million. The stock has a 50-day moving average price of $2.44 and a 200 day moving average price of $2.97.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm’s revenue was up 175.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) EPS. Equities analysts forecast that Celldex Therapeutics will post ($1.04) EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.